Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 42.39 -5.94 (-12.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Ionis Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 Next > Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed May 20, 2022 Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter. Via Benzinga What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals May 09, 2022 Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: Via Benzinga Recap: Ionis Pharmaceuticals Q1 Earnings May 04, 2022 Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints May 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Expert Ratings For Ionis Pharmaceuticals April 01, 2022 Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: Via Benzinga Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks March 17, 2022 Via Benzinga What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals February 01, 2022 Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: Via Benzinga How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call April 25, 2022 Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. Via Benzinga 7 Potential Biotech Stocks Buyout Targets in 2022 April 21, 2022 Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. Via InvestorPlace Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol April 04, 2022 Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have Via Benzinga Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment March 28, 2022 Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week. Via Investor's Business Daily Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints March 28, 2022 Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have Via Benzinga Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble January 31, 2022 Pfizer signed on to develop a high triglycerides treatment in November 2019. Via Investor's Business Daily Why Are Ionis Pharmaceuticals Shares Tanking Today? January 31, 2022 Pfizer Inc (NYSE: PFE) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) Via Benzinga Why Cramer Likes Ferguson And Stanley Black & Decker March 25, 2022 On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he... Via Benzinga Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More March 11, 2022 Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... Via Benzinga Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More March 02, 2022 Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... Via Benzinga Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More February 25, 2022 Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 March 01, 2022 Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... Via Benzinga Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More February 23, 2022 Benzinga’s Daily Brief On Trending Tickers highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... Via Benzinga Benzinga's Daily Brief On Trending Tickers For Feb. 22, 2022: Tesla, GameStop, Lexicon And More February 22, 2022 Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... Via Benzinga Bear Market Bets In Biotech February 07, 2022 Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. Via Talk Markets BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock? February 01, 2022 Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12... Via Benzinga Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot? January 31, 2022 Currently, analysts expect Moderna sales to drop off after 2022. Via Investor's Business Daily Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA January 31, 2022 Today's 5 Stock Ideas: Netflix (NFLX) - Shares up premarket. Citigroup upgraded the stock from Neutral to Buy and announced a $450 price target. Also, Co-CEO Reed Hastings... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 31, 2022 Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1... Via Benzinga Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder January 24, 2022 The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session January 20, 2022 This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... Via Benzinga Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? January 14, 2022 One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... Via Benzinga The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week January 02, 2022 Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. Via Talk Markets < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.